Navigation Links
Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
Date:2/22/2011

wn University and his B.S. in biochemistry and cell biology from the University of California, San Diego. He is the author of more than 10 key publications and presentations detailing the use of gene therapy and oncolytic viruses to treat cancer. He is board certified in hematology, oncology and internal medicine.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two Phase 2 clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 clinical trial, and a Phase 2 study of JX-594 in combination with sorafenib. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target and cause destruction of a variety of common cancer types. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the ablation of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
2. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
3. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
4. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Closes $5 Million First Tranche of Series C Financing
7. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
8. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
9. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
10. ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors
11. Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 ... of leading Immunologists, Principle Investigators, scientists in the ... J Malemud, Professor at Case Western Reserve University ... his keynote address on “The effects of ... production of matrix metalloproteinase-9”. Arya Biragyn, a Senior ...
(Date:7/29/2014)... 2014 SoundConnect , an ... is proud to announce the strategic additions of ... their Boston, Charleston and Atlanta offices. SoundConnect’s ... demand for hosted solutions, collaboration and mobility that ... cost. , SoundConnect was founded in 2004, with ...
(Date:7/29/2014)... have hurdled a number of significant technological challenges ... observing technology originally created for the James Webb ... Investigator Harvey Moseley, a scientist at NASA,s Goddard ... that electrostatically actuated microshutter arrays that is, ... are as functional as the current technology,s magnetically ...
(Date:7/29/2014)... DIEGO , July 29, 2014   Sequenom, ... sciences company that provides innovative genetic analysis solutions, and ... of esoteric laboratory services in the United ... noninvasive prenatal testing patents and applications. "We ... innovation, and patient care, and we welcome the opportunity ...
Breaking Biology Technology:Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3SoundConnect Organization and Culture is Evolving 2Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4
... Calif., Aug. 11 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group ... second quarter of 2008 ended June 30 were,$3,027,497 ... for the second,quarter of 2007. Revenues for the ... from the previous year., The significant revenue ...
... Calif., Aug. 11 Telik, Inc.,(Nasdaq: TELK ) reported ... the second quarter ended June 30, 2008, compared with a ... comparable period in 2007. The,$13.6 million net loss for the ... charge related to auction rate securities, which,is reflected in interest ...
... least half of shipments by the end of ... today announced that it will begin shipment of ... to U.S. customers,for the 2008-2009 influenza season. The ... Evaluation and Research (CBER) released the,first lots of ...
Cached Biology Technology:Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 2Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 3Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 4Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 5Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 6Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 7Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 8Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 9Telik Announces Financial Results For 2008 Second Quarter 2Telik Announces Financial Results For 2008 Second Quarter 3Telik Announces Financial Results For 2008 Second Quarter 4GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 2GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 3GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 4
(Date:7/30/2014)... A group of researchers from the University of Helsinki ... experimentally to reproduce in mice morphological changes which have ... gradual modifications in the embryonic development of mice teeth, ... morphologically are very similar to those observed in the ... millions of years ago. , To modify the ...
(Date:7/30/2014)... is pleased to announce its new relationship with the ... and CINP will partner to publish International Journal ... open-access journal. , Alan Frazer, Editor-in-Chief of IJNP ... expertise of OUP will further facilitate the goal for ... very leading journals within neuropsychopharmacology. The conversion of the ...
(Date:7/30/2014)... $1 million from the Cornelia Cogswell Rossi Foundation to ... , The newly established Connie Cogswell Rossi ... a greater breadth and depth of knowledge of neurobehavioral ... of research to improve human health. , The new ... Laboratory and its external partners, supporting research to enhance ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2OUP to partner with the International College of Neuropsychopharmacology 2Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
... (August 2, 2013) In a new observational study ... researchers looked at the association of grape consumption, in ... raisins and 100% grape juice with the diet ... children and adults. Their findings suggest that, among adults ...
... University of Toronto Engineering professor Ben Hatton is turning ... the energy leaks from windows. In an article in ... his colleagues at Harvard University describe a novel process to ... buildings cool during the summer. Their "bio-inspired approach to ...
... . . . By substituting lignin for ... have developed a process that requires fewer steps and ... ReNEW-PRO, is a low-cost lithium-ion battery anode made inexpensively ... pulp and paper industry. ReNEW-PRO was developed in collaboration ...
Cached Biology News:Grape consumption associated with healthier eating patterns in US children and adults 2Bio-inspired design may lead to more energy efficient windows 2August 2013 story tips from Oak Ridge National Laboratory 2
...
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes...
... derived from the Spodoptera frugiperda Sf21 cell line ... transfections, plaque assays, virus production, and protein expression. ... optimizes recovery of viable cells after thawing. They ... Cell Medium and can also be grown in ...
... premium quality recombinant form of Thermus aquaticus ... for a wide range of PCR applications. ... performance, each preparation is extensively tested in ... DNA Polymerase possesses an integral 5′→3′ exonuclease ...
Biology Products: